Skip to main content

By Biocat

The Inkemia IUCT Group has opened a commercial branch in the Colombian capital of Bogota, which is one more step in their strategic internationalization plan. In the first stage, the high-tech SME holding company aims to incentivize the commercialization of their knowledge transfer business area and later, after they have completed an expected capital increase of between €2 and €2.5 millions, they will intensify their presence in this market with more direct activity that goes beyond a commercial presence. To establish the Colombian delegation, the company will call on their experience in previous expansion processes, which began in Japan and Brazil and later extended to Poland and Argentina.

The fact is that Colombia, with a population of 47 million inhabitants and the fourth largest economy in Latin America, is highly attractive for Inkemia IUCT, which sees it in a favorable context given the significant development of oil processing and the stable political climate over the past ten years. In addition to the fact that Colombia’s GDP grew 5.9% in 2011, the company also highlights that the country’s priorities coincide with theirs, like promoting and supporting R&D in the oil and bioenergy sectors and growing the cosmetics, pharmaceutical and biotechnology industries based on natural products.

Based in Mollet del Vallès (Barcelona), Inkemia IUCT is the second Catalan biotech firm to go public on the Alternative Stock Market (MAB), after AB-Biotics. Executive president of the group, Dr. Josep Castells, told Biocat in an interview that the company’s future growth will also “encompass moving into France and the United States."

Sign up for our newsletters

Stay up-to-date on the latest news, events and trends in the BioRegion.